Nature Search

Murine Hybridoma Antibodies Enhance Bactericidal Activity of Human Cord Blood against K1 Escherichia coli Strains

Kwang Sik Kim
Alan S Cross
Jerald Sadof
Research01 Dec 1990
Pediatric Research

Volume: 28, P: 667-670
Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial

In this study, the authors report that post-vaccination neutralizing and binding antibody levels in the ENSEMBLE trial associate with Ad26.COV2.S vaccine efficacy (VE) against severe-critical COVID-19, with substantial VE even at unquantifiable neutralizing antibody titer.

Lindsay N. Carpp
Ollivier Hyrien
Griet A. Van Roey
ResearchOpen Access12 Nov 2024
Nature Communications

Volume: 15, P: 1-18
Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

SARS-CoV-2 variants with mutations in spike have emerged during the pandemic. Magaret et al. show that in Latin America, efficacy of the Ad26.COV2.S vaccine against moderate to severe–critical COVID-19 varied by sequence features, antibody escape scores, and neutralization impacting features of the SARS-CoV-2 variant.

Craig A. Magaret
Li Li
Peter B. Gilbert
ResearchOpen Access11 Mar 2024
Nature Communications

Volume: 15, P: 1-22
Advances in tuberculosis vaccine strategies

Yasir Skeiky and Jerry Sadoff outline the current state of play in the development of effective vaccines againstMycobacterium tuberculosis. Promising strategies include the use of modified recombinant BCG, live attenuated M. tuberculosisand subunit vaccines alone or in prime?boost regimens to optimize immunity and vaccine safety.

Yasir A. W. Skeiky
Jerald C. Sadoff
Comments & Opinion01 Jun 2006
Nature Reviews Microbiology

Volume: 4, P: 469-476
Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

Protective efficacy of novel vaccine candidates in rhesus monkeys opens new paths for the development of an HIV-1 vaccine.

Dan H. Barouch
Jinyan Liu
Nelson L. Michael
Research04 Jan 2012
Nature

Volume: 482, P: 89-93
1122 TREATMENT OF EXPERIMENTAL E. COLI (EC) INFECTION WITH THE COMBINATION OF CHEMOTHERAPY AND IMMUNOTHERAPY

Kwang Sik Kim
Carol Wass
B F Anthony
Research01 Apr 1985
Pediatric Research

Volume: 19, P: 297
Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters

Lisa H. Tostanoski
Abishek Chandrashekar
Dan H. Barouch
ResearchOpen Access10 Jan 2022
npj Vaccines

Volume: 7, P: 1-6
Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial

Gold-standard evidence for correlates of protection is provided by analysis of a randomized phase 3 trial of Ad26.COV2.S for protection against moderate to severe-critical COVID-19 disease.

Youyi Fong
Adrian B. McDermott
Ruben O. Donis
Research10 Nov 2022
Nature Microbiology

Volume: 7, P: 1996-2010
Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Analysis of the immunogenicity of the Ad26.COV2.S vaccine against the B1.351 and P.1 SARS-CoV-2 variants of concern shows reduced neutralization antibody titres, but comparable T cell responses and antibody-dependent effector functions.

Galit Alter
Jingyou Yu
Dan H. Barouch
ResearchOpen Access09 Jun 2021
Nature

Volume: 596, P: 268-272
Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines

Van Rampelbergh et al investigate the clinical characteristics and outcomes of vaccine-induced immune thrombocytopenia and thrombosis (VITT) following vaccination with 2 adenovirus vector COVID-19 vaccines: Ad26.COV2.S and ChAdOx1 nCoV-19. No strong evidence for a clinically relevant difference in VITT occurring after either vaccine.

Rian Van Rampelbergh
Sue Pavord
Frank Struyf
ResearchOpen Access10 May 2025
Communications Medicine

Volume: 5, P: 1-7
Absolute quantitation of binding antibodies from clinical samples

Chan Tang
Annemiek Verwilligen
Daniel J. Stieh
ResearchOpen Access06 Jan 2024
npj Vaccines

Volume: 9, P: 1-12
Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine

Melissa Nyendak
Gwendolyn M. Swarbrick
David M. Lewinsohn
ResearchOpen Access02 Nov 2016
Scientific Reports

Volume: 6, P: 1-12

Search

Murine Hybridoma Antibodies Enhance Bactericidal Activity of Human Cord Blood against K1 Escherichia coli Strains

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial

Quantifying how single dose Ad26.COV2.S vaccine efficacy depends on Spike sequence features

Advances in tuberculosis vaccine strategies

Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys

1122 TREATMENT OF EXPERIMENTAL E. COLI (EC) INFECTION WITH THE COMBINATION OF CHEMOTHERAPY AND IMMUNOTHERAPY

Passive transfer of Ad26.COV2.S-elicited IgG from humans attenuates SARS-CoV-2 disease in hamsters

Immune correlates analysis of the ENSEMBLE single Ad26.COV2.S dose vaccine efficacy clinical trial

Immunogenicity of Ad26.COV2.S vaccine against SARS-CoV-2 variants in humans

Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines

Absolute quantitation of binding antibodies from clinical samples

Adenovirally-Induced Polyfunctional T Cells Do Not Necessarily Recognize the Infected Target: Lessons from a Phase I Trial of the AERAS-402 Vaccine

Search

Quick links

Search

Filter By:

Search

Quick links